AVNS · Avanos Medical, Inc. · Stock research

Current Thesis

The take-private is effectively closed. On 2026-07-22 Avanos stockholders approved the all-cash acquisition by American Industrial Partners (AIP) at $25.00/share, with roughly 99.75% of votes cast in favor (about 74.96% of shares outstanding). All required regulatory clearances were received 2026-07-02, and both parties guide completion no later than 2026-07-27, at which point the common stock delists from the NYSE. The independent confirmation is index-mechanical: S&P announced 2026-07-20 that V2X replaces AVNS in the S&P SmallCap 600 effective before the open on Monday 2026-07-27 — committees only pull a name when a deletion is locked. For a narrative-momentum mandate there is nothing here: price is contractually pinned to the cash number, the residual discount is a few days of arb yield, and the security disappears at close. No leg to buy, no trend to ride, no catalyst that pays beta.

Bullish and bearish views on Avanos Medical, Inc.

The model's bull view on Avanos Medical, Inc. (AVNS), in brief: Deal risk is essentially retired. Regulatory approvals in hand as of 2026-07-02; shareholder approval delivered 2026-07-22 at ~99.75% of votes cast — the two most common arb-killers (financing, then vote) are both cleared. No financing condition. The 2026-04-14 terms fund the… The bear view: There is no momentum trade and no equity to trade after Monday. Both cases follow in full.

Bull Case

• Deal risk is essentially retired. Regulatory approvals in hand as of 2026-07-02; shareholder approval delivered 2026-07-22 at ~99.75% of votes cast — the two most common arb-killers (financing, then vote) are both cleared.
• No financing condition. The 2026-04-14 terms fund the $25.00 cash via an AIP equity commitment (EV $1.272B, a 72.1% premium to the 2026-04-13 close of ~$14.53); there was never a lender out to fail.
• Standalone business is healthy, capping any break downside. Q1 print (2026-05-05): Adj EPS $0.22 vs $0.14 consensus, sales $182.2M vs $170M — a collapsed deal would land on improving fundamentals rather than a distressed base.
• The only "bull" left is arb yield to a dated close. With completion guided by 2026-07-27, duration is measured in days — a return this book does not harvest.

Bear Case

• There is no momentum trade and no equity to trade after Monday. Narrative velocity, multiple expansion and upside beta are all zero;
• The residual tail is asymmetric to the downside. A last-session bust — improbable now that the vote is counted and regulators are cleared — re-rates toward the pre-deal ~$14.53 zone, a 40%+ air pocket from the $25.00 pin even on a clean Q1.
• A financial sponsor removes topping-bid optionality. AIP is private equity, not a strategic with synergies; with the vote done and delisting scheduled, a superior proposal at this stage is a near-nil base rate.
• "Overbought" screens on this name are artifacts. Benzinga's RSI-90 flag (2026-05-04, "may collapse this month") is the residue of the 2026-04-14 ~69% deal gap, not distribution — a cash-clamped price does not reprice off momentum oscillators.

Setup & Price Structure

Shares gapped from the ~$14.53 close (2026-04-13) into the low-$24s on the 2026-04-14 announcement and have held a tight band just beneath the $25.00 consideration ever since, with the discount compressing toward zero as the 2026-07-22 vote and ~2026-07-27 close arrived. Announcement-day volume spiked, then bled back to arb-desk baseline. Moving averages, EMAs, breakout shelves and RSI carry no signal on a price set by contract; the only chart event that would matter is a discrete gap below the band, which would mean the tape is pricing a break rather than a completion. Absent that, there is no trend, no support test, and no parabola — just a spread grinding into settlement, followed by delisting.

Catalyst Calendar (next 30 days)

No upcoming dated catalysts on file — the dated entries below have passed.

Elapsed catalysts

• ~2026-07-27 (guided) — merger completion & NYSE delisting. Both parties guide close no later than this date; on completion holders receive $25.00 cash and the stock stops trading. (passed 13d ago)
• 2026-07-27 (confirmed) — S&P SmallCap 600 removal effective before the open. V2X replaces AVNS (announced 2026-07-20); forced index-fund selling clears mechanically into the close. (passed 13d ago)
• Vote already counted — 2026-07-22 special meeting (ELAPSED). Approved at ~99.75% of votes cast; no further shareholder gate remains. (passed 18d ago)
• No earnings, guidance, or standalone company catalyst is scheduled — the Q1 print (2026-05-05) is the last operating datapoint and is moot to a pinned price. (passed 96d ago)

What Would Change Our Mind

The dormant read reopens only on evidence the deal fails to settle: a daily close below $22.50 — a >10% break of the $25.00 cash floor — would signal a last-minute completion problem (a waiver dispute or MAE scare, though regulators cleared 2026-07-02 and the vote passed 2026-07-22) and reintroduce a modelable standalone trade back toward the ~$14.53 pre-deal zone. Symmetrically, an improbable competing proposal printing above $25.00 before close would reopen the name to the upside. Neither is the base case; the base case is settlement on/around 2026-07-27 and delisting, after which there is no US-listed equity to analyze.

Correlation Notes

AVNS trades on deal mechanics, not sector beta — its correlation to medtech peers, small-cap indices (its own S&P 600 membership ends 2026-07-27) and rate-sensitive healthcare baskets has been near zero since the 2026-04-14 gap. The only meaningful covariate is deal-completion risk itself, which is idiosyncratic and now largely resolved. As a data point for the special-situations sleeve, it reads as a clean go-private that never developed a bust-or-bump edge: financial sponsor, no financing condition, fast regulatory path, overwhelming vote. It is a template for why fixed-price cash arb is not a narrative-momentum instrument, not a name to redeploy into.